Copertina

Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Hong Xu, Wenqi Wu, Yanan Jiang, Jinhuan Wang, Yixin Zhai, Zhigang Zhao
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Cancer Medicine
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Imeglimin Exerts Anti‐Tumor Activity in Multiple Myeloma Through Affecting Energy Metabolism and Downregulating IL ‐16 Expression
di: Jifeng Jiang, et al.
Pubblicazione: (2026)

XPO1 serves as a prognostic marker involving AKT/MAPK/TGFBR1 pathway in OSCC
di: Ying Han, et al.
Pubblicazione: (2024)

Prognostic Implications of Thrombocytopenia in Chinese Patients With Newly Diagnosed Multiple Myeloma
di: Xiaojing Li, et al.
Pubblicazione: (2025)

Current Knowledge of Immune Checkpoint Inhibitor‐Induced Thrombocytopenia: Epidemiology, Mechanisms, and Management
di: Youran Dai, et al.
Pubblicazione: (2026)

Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma
di: Sijia Yan, et al.
Pubblicazione: (2025)

Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2− Metastatic Breast Cancer
di: Adam M. Brufsky, et al.
Pubblicazione: (2025)

Incidence, Clinical Features, and Prognostic Value of New‐Onset Renal Impairment in Multiple Myeloma
di: Xiang Liu, et al.
Pubblicazione: (2025)

Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors
di: Wenke Li, et al.
Pubblicazione: (2025)

Concomitant Usage of H1‐Antihistamines and Immune Checkpoint Inhibitors on Cancer Patient Survival
di: Yin Leung, et al.
Pubblicazione: (2025)

Talquetamab‐Related Dysgeusia in Multiple Myeloma Compared to BCMA ‐Targeted Bispecifics and High‐Dose Melphalan
di: Anna Fleischer, et al.
Pubblicazione: (2025)

Correction to “Incidence, Clinical Features, and Prognostic Value of New‐Onset Renal Impairment in Multiple Myeloma”
Pubblicazione: (2026)

Induction Chemotherapy‐Related Covert Cardiac Remodeling in Pre‐Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Retrospective Observational Study
di: Chang Dai, et al.
Pubblicazione: (2024)

Characterization and Management of Cytokine Release Syndrome From the MonumenTAL ‐1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
di: Niels W. C. J. van de Donk, et al.
Pubblicazione: (2025)

5‐Hydroxymethylcytosine Profiles of cfDNA in Urine as Diagnostic, Differential Diagnosis and Prognostic Markers for Multiple Myeloma
di: Weiwei Xie, et al.
Pubblicazione: (2024)

PARP Inhibitors in the Treatment of Prostate Cancer: An Analysis of the Clinical Trial Landscape
di: Yanru Chen, et al.
Pubblicazione: (2025)

The Critical Role of Inhibitor of Differentiation 4 in Breast Cancer: From Mammary Gland Development to Tumor Progression
di: Yuhang Song, et al.
Pubblicazione: (2025)

Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti‐CD38 Monoclonal Antibodies: A Systematic Review
di: Chia Jie Tan, et al.
Pubblicazione: (2025)

Efficacy and Safety of Immune Checkpoint Inhibitors in the Treatment of Hematologic Malignancies: An Umbrella Review of Systematic Reviews and Meta‐Analyses
di: Zhengyu Yu, et al.
Pubblicazione: (2026)

An Open‐Label, Single‐Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non‐Small Cell Lung Cancer After First‐Line PD ‐(L)1 Inhibitor
di: Xun Shi, et al.
Pubblicazione: (2025)

Pilot Study of Cannabidiol for Treatment of Aromatase Inhibitor‐Associated Musculoskeletal Symptoms in Breast Cancer
di: Nicole M. G. Fleege, et al.
Pubblicazione: (2025)

The Influence of Performance Status, Inflammation, and Nutrition on the Impact of SGLT2 Inhibitors on Cancer Outcomes
di: Diego Rivas‐Otero, et al.
Pubblicazione: (2025)

Impact of Perioperative Proton Pump Inhibitors on Renal Cancer Progression. A Retrospective Study
di: Nicolas Cortes‐Mejia, et al.
Pubblicazione: (2026)

Monotherapy With Immune Checkpoint Inhibitors in Patients With Recurrent and/or Metastatic Sinonasal Squamous Cell Carcinoma
di: Alexander Lein, et al.
Pubblicazione: (2025)

The Efficacy and Safety of Albumin‐Bound Paclitaxel Combined With Anlotinib and PD‐1/L1 Inhibitors For Treating Patients With Extensive‐Stage Small Cell Lung Cancer and Brain Metastasis: A Retrospective Cohort Study
di: Xiaobing Li, et al.
Pubblicazione: (2024)

Associations Between Pre‐Existing Cardiovascular Disease and Survival in Patients on Immune Checkpoint Inhibitor Therapy
di: Aditya Mahadevan, et al.
Pubblicazione: (2025)

The Multi‐Kinase Inhibitor GZD824 (Olverembatinib) Shows Pre‐Clinical Efficacy in Endometrial Cancer
di: Dongli Liu, et al.
Pubblicazione: (2024)

Plasma Fibrinogen Predicts Response to Immune Checkpoint Inhibitor by Inflammatory Tumor Microenvironment in Esophageal Cancer
di: Keiso Ho, et al.
Pubblicazione: (2026)

Mutation in CDC42 Gene Set as a Response Biomarker for Immune Checkpoint Inhibitor Therapy
di: Kun Wang, et al.
Pubblicazione: (2025)

Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial
di: Ya‐Lan Zhou, et al.
Pubblicazione: (2025)

Long‐Term Trends and Projections of Multiple Myeloma Across Three Continents: A Comparative Study of China, the United States of America, the Russian Federation, England and France (1990–2036)
di: Huiqiang Wu, et al.
Pubblicazione: (2025)

Real‐World Efficacy of Nab‐Paclitaxel Plus Capecitabine and a PD ‐1 Inhibitor in Metastatic or Locally Advanced Esophageal Cancer
di: Yun Wang, et al.
Pubblicazione: (2026)

Important Roles of PI3K / AKT Signaling Pathway and Relevant Inhibitors in Prostate Cancer Progression
di: Rui Wang, et al.
Pubblicazione: (2024)

Influence of Gut Microbiota on Response to Immune Check Point Inhibitors in MASLD Patients With HCC : Unraveling the Connection
di: Mazen Elsheikh, et al.
Pubblicazione: (2026)

Emergence of BRCA Reversion Mutations in Prostate Cancer Prior to PARP Inhibitor Exposure: Clinical and Therapeutic Implications
di: Douglas I. Lin, et al.
Pubblicazione: (2026)

Moving Beyond G‐CSF Mobilization—Learning From a 15‐Year Experience of Different Stem Cell Mobilization Regimens in Multiple Myeloma
di: Sumeet Mirgh, et al.
Pubblicazione: (2025)

First‐In‐Human Dose Finding Study of Venadaparib (IDX‐1197), a Potent and Selective PARP Inhibitor, in Patients With Advanced Solid Tumors
di: Sung‐Bae Kim, et al.
Pubblicazione: (2025)

Correction to “Induction of Resistance to Neurotrophic Tropomyosin‐Receptor Kinase Inhibitors by HMGCS2 via a Mevalonate Pathway”
Pubblicazione: (2024)

A Critical Analysis of the Impact of Etoposide as a Topoisomerase II Inhibitor in Cervical Cancer Treatment: A Review
di: Nikitha Kotian, et al.
Pubblicazione: (2026)

Navigating the Prognostic Complexity of IgH Cytogenetic Abnormalities in Multiple Myeloma Among Diverse IgH Cytogenetic Abnormalities–Involved High‐Risk Stratifications
di: Yanqiu Xiong, et al.
Pubblicazione: (2025)

BTK Inhibitor Synergizes With CD19 ‐Targeted Chimeric Antigen Receptor‐T Cells in Patients With Relapsed or Refractory B‐Cell Lymphoma: An Open‐Label Pragmatic Clinical Trial
di: Wenjing Luo, et al.
Pubblicazione: (2025)